Cargando…

Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course

BACKGROUND: Myelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS. MOGAD can present with a monophasic or relapsing disease course with distinct clinical manifestations.However, data on the disease course an...

Descripción completa

Detalles Bibliográficos
Autores principales: Rechtman, Ariel, Brill, Livnat, Zveik, Omri, Uliel, Benjamin, Haham, Nitzan, Bick, Atira S., Levin, Netta, Vaknin-Dembinsky, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987978/
https://www.ncbi.nlm.nih.gov/pubmed/35401390
http://dx.doi.org/10.3389/fneur.2022.867190
_version_ 1784682862604189696
author Rechtman, Ariel
Brill, Livnat
Zveik, Omri
Uliel, Benjamin
Haham, Nitzan
Bick, Atira S.
Levin, Netta
Vaknin-Dembinsky, Adi
author_facet Rechtman, Ariel
Brill, Livnat
Zveik, Omri
Uliel, Benjamin
Haham, Nitzan
Bick, Atira S.
Levin, Netta
Vaknin-Dembinsky, Adi
author_sort Rechtman, Ariel
collection PubMed
description BACKGROUND: Myelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS. MOGAD can present with a monophasic or relapsing disease course with distinct clinical manifestations.However, data on the disease course and disability outcomes of these patients are scarce. We aim to compare brain volumetric changes for MOGAD patients with different disease phenotypes and HCs. METHODS: Brain magnetic resonance imaging (MRI) scans and clinical data were obtained for 22 MOGAD patients and 22 HCs. Volumetric brain information was determined using volBrain and MDbrain platforms. RESULTS: We found decreased brain volume in MOGAD patients compared to HCs, as identified in volume of total brain, gray matter, white matter and deep gray matter (DGM) structures. In addition, we found significantly different volumetric changes between patients with relapsing and monophasic disease course, with significantly decreased volume of total brain and DGM, cerebellum and hippocampus in relapsing patients during the first year of diagnosis. A significant negative correlation was found between EDSS and volume of thalamus. CONCLUSIONS: Brain MRI analyses revealed volumetric differences between MOGAD patients and HCs, and between patients with different disease phenotypes. Decreased gray matter volume during the first year of diagnosis, especially in the cerebrum and hippocampus of MOGAD patients was associated with relapsing disease course.
format Online
Article
Text
id pubmed-8987978
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89879782022-04-08 Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course Rechtman, Ariel Brill, Livnat Zveik, Omri Uliel, Benjamin Haham, Nitzan Bick, Atira S. Levin, Netta Vaknin-Dembinsky, Adi Front Neurol Neurology BACKGROUND: Myelin oligodendrocyte glycoprotein antibody disorders (MOGAD) have evolved as a distinct group of inflammatory, demyelinating diseases of the CNS. MOGAD can present with a monophasic or relapsing disease course with distinct clinical manifestations.However, data on the disease course and disability outcomes of these patients are scarce. We aim to compare brain volumetric changes for MOGAD patients with different disease phenotypes and HCs. METHODS: Brain magnetic resonance imaging (MRI) scans and clinical data were obtained for 22 MOGAD patients and 22 HCs. Volumetric brain information was determined using volBrain and MDbrain platforms. RESULTS: We found decreased brain volume in MOGAD patients compared to HCs, as identified in volume of total brain, gray matter, white matter and deep gray matter (DGM) structures. In addition, we found significantly different volumetric changes between patients with relapsing and monophasic disease course, with significantly decreased volume of total brain and DGM, cerebellum and hippocampus in relapsing patients during the first year of diagnosis. A significant negative correlation was found between EDSS and volume of thalamus. CONCLUSIONS: Brain MRI analyses revealed volumetric differences between MOGAD patients and HCs, and between patients with different disease phenotypes. Decreased gray matter volume during the first year of diagnosis, especially in the cerebrum and hippocampus of MOGAD patients was associated with relapsing disease course. Frontiers Media S.A. 2022-03-24 /pmc/articles/PMC8987978/ /pubmed/35401390 http://dx.doi.org/10.3389/fneur.2022.867190 Text en Copyright © 2022 Rechtman, Brill, Zveik, Uliel, Haham, Bick, Levin and Vaknin-Dembinsky. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Rechtman, Ariel
Brill, Livnat
Zveik, Omri
Uliel, Benjamin
Haham, Nitzan
Bick, Atira S.
Levin, Netta
Vaknin-Dembinsky, Adi
Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course
title Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course
title_full Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course
title_fullStr Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course
title_full_unstemmed Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course
title_short Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course
title_sort volumetric brain loss correlates with a relapsing mogad disease course
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987978/
https://www.ncbi.nlm.nih.gov/pubmed/35401390
http://dx.doi.org/10.3389/fneur.2022.867190
work_keys_str_mv AT rechtmanariel volumetricbrainlosscorrelateswitharelapsingmogaddiseasecourse
AT brilllivnat volumetricbrainlosscorrelateswitharelapsingmogaddiseasecourse
AT zveikomri volumetricbrainlosscorrelateswitharelapsingmogaddiseasecourse
AT ulielbenjamin volumetricbrainlosscorrelateswitharelapsingmogaddiseasecourse
AT hahamnitzan volumetricbrainlosscorrelateswitharelapsingmogaddiseasecourse
AT bickatiras volumetricbrainlosscorrelateswitharelapsingmogaddiseasecourse
AT levinnetta volumetricbrainlosscorrelateswitharelapsingmogaddiseasecourse
AT vaknindembinskyadi volumetricbrainlosscorrelateswitharelapsingmogaddiseasecourse